BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma Stock Forecast

Stock Price Forecast

The 11 analysts with 12-month price forecasts for BridgeBio Pharma stock have an average target of 53, with a low estimate of 45 and a high estimate of 95. The average target predicts an increase of 54.79% from the current stock price of 34.24.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$45	$53	$50	$95
Change	+31.43%	+54.79%	+46.03%	+177.45%

Analyst Ratings

The average analyst rating for BridgeBio Pharma stock from 12 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25	Apr '25
Strong Buy	5	5	5	5	5	5
Buy	6	6	6	6	6	6
Hold	2	2	2	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	13	13	13	12	12	12

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $49 → $53	Strong Buy	Maintains	$49 → $53	+54.79%	Apr 15, 2025
Joshua Smith Redburn Atlantic	Redburn Atlantic	Strong Buy Initiates $50	Strong Buy	Initiates	$50	+46.03%	Mar 31, 2025
Anupam Rama JP Morgan	JP Morgan	Buy Maintains $44 → $50	Buy	Maintains	$44 → $50	+46.03%	Mar 24, 2025
David Lebowitz Citigroup	Citigroup	Strong Buy Maintains $45 → $49	Strong Buy	Maintains	$45 → $49	+43.11%	Feb 21, 2025
Josh Schimmer Cantor Fitzgerald	Cantor Fitzgerald	Buy Reiterates $95	Buy	Reiterates	$95	+177.45%	Feb 21, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

254.93M

Increased by 14.88%

from 221.90M

Revenue Next Year

563.97M

Increased by 121.23%

from 254.93M

EPS This Year

-3.92

from -2.88

EPS Next Year

-2.78

from -3.92

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	8.25M	69.72M	77.65M	9.30M	221.90M	254.93M	563.97M	1.12B
Revenue Growth	-79.66%	745.15%	11.38%	-88.02%	2,285.27%	14.88%	121.23%	97.88%
EPS	-3.80	-3.90	-3.26	-3.95	-2.88	-3.92	-2.78	-0.55
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	20	17	15

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	401.1M	801.3M	1.5B
Avg	254.9M	564.0M	1.1B
Low	138.2M	387.1M	752.6M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	80.8%	214.3%	160.5%
Avg	14.9%	121.2%	97.9%
Low	-37.7%	51.8%	33.5%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	-2.66	-1.67	1.01
Avg	-3.92	-2.78	-0.55
Low	-4.53	-3.75	-2.79

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.